1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

A Product and Pipeline Analysis of the Global Diabetes Therapeutics Market

  • April 2014
  • 88 pages
  • Frost & Sullivan
Report ID: 2115020

Summary

Table of Contents

The marketed and development product landscape for diabetes therapeutics is becoming crowded with multiple products with little differentiation. However, there is still ample room for growth through the introduction of novel therapies that fill therapeutic gaps left by available products. Comprehensive information on market background and global overview and analysis of drug development, detailed product and pipeline analysis by market segment, drug class, and stage of development, and detailed product profiles for key marketed and late-stage products is included in the study. Also included are time-sensitive details such as new product launch timelines, cardiovascular outcomes trials timelines, and patent expirations.


Executive Summary

Drug development activity for diabetes shows no signs of slowing despite the many
challenges associated with entry into this crowded and demanding market. The enormity
of the growing patient population coupled with substantial gaps left by available therapies
continues to motivate numerous global participants.

Regulatory hurdles are significant, with cardiovascular safety at the forefront of the
ideal product profile.

Product differentiation and prescribing decisions are becoming increasingly difficult
with the availability of multiple competing drug classes.

Drug developers are responding with several pipeline advancements and new targets.
Overall, the pipeline of non-insulin drug candidates from Phase 1 through pre-registration
has grown from approximately x to x since Q1 2013.

The availability of orally administered antidiabetic biopharmaceuticals is getting closer to
a reality, with x oral insulin analogs and x oral glucagon-like peptide-1 (GLP-1)
analogs/agonists in various stages of development, along with an inhalable insulin
(Mannkind’s Afrezza) currently under US Food and Drug Administration (FDA) review.

Other noteworthy developments in the insulin market include the imminent arrival of
several concentrated insulins to meet the needs of very obese or highly insulin-resistant
patients and the clinical advancement of several ultra-rapid-acting insulin analogs with
improved efficacy and convenience.

The non-insulin segment of the market is also undergoing some dynamic changes,
notably the advancement of x GLP-1/insulin combination products (Sanofi/Zealand’s
LixiLan and Novo Nordisk’s IDegLira) to late-stage development. There also seems to be
a resurgence of interest in the glucokinase activator (GKA) target, with x candidates in
the pipeline.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

  • $ 6995
  • Industry report
  • March 2017
  • by GBI Research

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products Summary Fatty liver disease (FLD) comprises a spectrum of chronic ...

Biosimilar Insulin Market Access

  • $ 5000
  • Industry report
  • March 2017
  • by Datamonitor Healthcare

Overview Biosimilar competition is providing payers with opportunities to contain costs in a category that accounts for a significant proportion of total drug expenditure. The launch of the biosimila ...

Diabetes Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Diabetes Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth ...

Insulin Markets In China

April 2017 $ 4000

Insulin Companies In China

April 2017 $ 1800

Download Unlimited Documents from Trusted Public Sources

Vaccine Market and Influenza Statistics in India

  • June 2017
    6 pages
  • Vaccine  

    Influenza  

    Diabetes  

  • India  

    United States  

View report >

Hormone and Therapy Market in Pakistan and the US

  • June 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Antidiabetics Market in the US

  • June 2017
    4 pages
  • Gliptins  

    Antidiabetics  

    Biguanide  

  • United States  

    World  

View report >

Related Market Segments :

Insulin

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.